Enliven Therapeutics, Inc. (ELVN) - Stock Analysis
Last updated: May 9, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
ElevateBio is riding strong momentum (~21% 21‑day gain, price ~20% above 21‑day SMA and a recent 52‑week high) after positive Phase 1b ENABLE data for ELVN‑001 (MMR ~69% at 24 weeks, durable responses) and clear plans for Phase 3; clustered late‑stage hematology catalysts plus a solid cash runway make it a high‑volatility but attractive near‑term clinical momentum trade.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: • Strong Liquidity • Ongoing Losses • Share Dilution ELVN has a very strong cash position and minimal debt, but with no revenue, ongoing losses, negative cash flow, dilution, and a still-rich valuation, the financial picture remains weak overall.
Price Behavior
Key Price Behavior Insights: • Lower highs • Near-term support • Reclaim needed Support Level: $40.3 to $40.8 Resistance Level: $41.6 to $42.4 ELVN is in a short-term pullback over the last month, holding near $40.3–$40.8 but needing a reclaim of $42.4 to shift back toward a healthier consolidation.
Sentiment & News
Key News Insights: • Mid-2026 data • Phase 3 start • Cash runway Enliven Therapeutics highlighted expected mid-2026 Phase 1 data for ELVN-001, planned Phase 3 ENABLE-2 initiation in 2H26, and a $452 million cash position that funds operations into 1H29.
AI Summary
ELVN has shifted from a financing-risk story to a well-capitalized, late-stage biotech where the investment case now hinges almost entirely on whether ELVN-001 can deliver convincing Phase 1 data and keep ENABLE-2 on track, making the stock a high-upside but highly binary catalyst trade rather than a balance-sheet concern.
Description
Enliven Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule kinase inhibitors for cancer treatment. Its lead programs include ELVN-001, in a Phase 1 study for chronic myeloid leukemia, and ELVN-002, recently activated in a Phase 1 trial for tumors with HER2 alterations; the company is headquartered in Boulder, Colorado.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Mar 26 | Apr 2 | ELVN | Enliven Therapeutics, Inc. | ElevateBio is riding strong momentum (~21% 21‑day gain, price ~20% above 21‑day SMA and a recent 52‑week high) after positive Phase 1b ENABLE data for ELVN‑001 (MMR ~69% at 24 weeks, durable responses) and clear plans for Phase 3; clustered late‑stage hematology catalysts plus a solid cash runway make it a high‑volatility but attractive near‑term clinical momentum trade. | Closed | -1.2% |